Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2026 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2026 Earnings Call Transcript May 7, 2026Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings Inc. (DNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Prescott Group Capital Management Phil Frohlich | 541,845 | $3,321,510 | 0.33% | |
| 2. | 0 | $0 | 0% | ||
| 3. | Walleye Capital Will England | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.82 | 625,000 | $514,750.00 | 2,356,874 | 2024-05-15 | Filing | |
| $0.91 | 297,619 | $271,815.43 | 718,540 | 2024-05-14 | Filing | |
| $1.28 | 400,000 | $512,000.00 | 1,731,874 | 2023-05-18 | Filing | |
| $1.28 | 350,000 | $448,000.00 | 420,921 | 2023-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.95 | 324 | $2,576.45 | 50,268 | 2026-04-17 | Filing | |
| $6.41 | 33,171 | $212,758.79 | 49,849 | 2026-04-13 | Filing | |
| $6.43 | 124,727 | $802,493.52 | 436,422 | 2026-04-10 | Filing | |
| $6.43 | 124,727 | $802,493.52 | 436,422 | 2026-04-10 | Filing | |
| $6.40 | 13,116 | $83,903.05 | 338,568 | 2026-04-09 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,642,347 | $22,327,587 | 0% | |
| 2. | 2,391,649 | $14,660,808 | 0.01% | |
| 3. | 1,914,428 | $11,735,444 | 0% | |
| 4. | 1,947,728 | $10,673,549 | 0.1% | |
| 5. | 1,661,587 | $10,185,528 | 0% |
News See All
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2025 Earnings Call Transcript
Daniel Waid Marshall: Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2025 Earnings Call Transcript November 6, 2025Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2025 Earnings Call Transcript
Daniel Waid Marshall: Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. I'm joined by Jason Kelly, our Co-Founder and CEO; and our new CFO, Steve Coen.
Billionaire Nicholas J. Pritzker's 8 Stocks with Huge Upside Potential
Nicholas J. Pritzker is the chairman and co-founder of Tao Capital Partners, a San Francisco-based venture capital firm established in 2013.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2025 Earnings Call Transcript May 6, 2025Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript February 25, 2025Ginkgo Bioworks Holdings, Inc. misses on earnings expectations.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q3 2024 Earnings Call Transcript
Megan LeDuc: Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Hedge Fund Resource Center